Department of Stomatology, Zibo Central Hospital, Zibo, Shandong, China.
Department of Stomatology, The Third Hospital of Jinan, Jinan, Shandong, China.
J Int Med Res. 2020 Aug;48(8):300060520934254. doi: 10.1177/0300060520934254.
Long noncoding (lnc)RNAs regulate multiple biological processes including cancer. Oral squamous cell carcinoma (OSCC) is a common malignancy with poor prognosis. We aimed to identify the function of lncRNA HOXA10 antisense RNA (HOXA10-AS) and its clinical significance.
We used differential expression analysis to identify aberrantly expressed lncRNAs associated with OSCC. We identified key genes related to HOXA10-AS and their biological functions using bioinformatics tools and functional enrichment analyses. We predicted the function of HOXA10-AS using gene set enrichment and variation analyses and analyzed proliferation markers at the mRNA and protein levels. Finally, we silenced HOXA10-AS using antisense oligonucleotide and assessed proliferation ability using a cell counting kit (CCK8) and clone formation assays.
In total, 506 aberrantly expressed lncRNAs were identified. HOXA10-AS was identified as a risk factor for OSCC and its expression was positively associated with tumor grade. We identified hub genes involved in regulating proliferation and predicted that HOXA10-AS is associated with an active cell cycle and increased proliferation. Silencing HOXA10-AS decreased proliferation in OSCC cell lines.
HOXA10-AS is involved in cell proliferation and silencing it decreases proliferation. Thus, HOXA10-AS could serve as prognostic biomarker and therapeutic target for OSCC.
长链非编码（lnc）RNAs 调节多种生物学过程，包括癌症。口腔鳞状细胞癌（OSCC）是一种预后不良的常见恶性肿瘤。我们旨在确定 lncRNA HOXA10 反义 RNA（HOXA10-AS）的功能及其临床意义。
我们使用差异表达分析来识别与 OSCC 相关的异常表达 lncRNAs。我们使用生物信息学工具和功能富集分析来鉴定与 HOXA10-AS 相关的关键基因及其生物学功能。我们使用基因集富集和变异分析预测 HOXA10-AS 的功能，并在 mRNA 和蛋白质水平分析增殖标记物。最后，我们使用反义寡核苷酸沉默 HOXA10-AS，并使用细胞计数试剂盒（CCK8）和克隆形成测定评估增殖能力。
总共鉴定出 506 个异常表达的 lncRNAs。HOXA10-AS 被鉴定为 OSCC 的危险因素，其表达与肿瘤分级呈正相关。我们鉴定出参与调节增殖的枢纽基因，并预测 HOXA10-AS 与细胞周期活跃和增殖增加有关。沉默 HOXA10-AS 可降低 OSCC 细胞系的增殖能力。
HOXA10-AS 参与细胞增殖，沉默它可降低增殖。因此，HOXA10-AS 可作为 OSCC 的预后生物标志物和治疗靶点。
